Gliclazide

Gliclazide

Systematic (IUPAC) name
N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4-methylbenzenesulfonamide
Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Legal status	?
Pharmacokinetic data
Half-life	10.4 hours
Identifiers
CAS number	21187-98-4 Y
ATC code	A10BB09
PubChem	CID 3475
DrugBank	DB01120
ChemSpider	3356 Y
UNII	G4PX8C4HKV Y
KEGG	D01599 Y
ChEBI	CHEBI:31654 Y
ChEMBL	CHEMBL427216 Y
Chemical data
Formula	C15H21N3O3S
Mol. mass	323.412 g/mol
SMILES O=S(=O)(c1ccc(cc1)C)NC(=O)NN3CC2CCCC2C3
InChI InChI=1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19) Y Key:BOVGTQGAOIONJV-UHFFFAOYSA-N Y
Y (what is this?)  (verify)

Gliclazide is an oral hypoglycemic (anti-diabetic drug) and is classified as a sulfonylurea. Gliclazide is the research of SERVIER- A French Multinational. In India original Gliclazide is marketed in original Brand name as " Diamicron XR 60 " by SERVIER subsidiary SERDIA Pharmaceuticals, while other companies promote copies are "Glizid" , Glyloc and Reclide in India . In the Philippines, Servier markets it as Diamicron MR, like in most countries across the world. Many generic equivalents are also available e.g. Glubitor-OD, Clizid. It is not marketed in the United States. A modified-release formulation is also marketed. Its classification has been ambiguous, as literature uses it as both a first-generation ^[1] and second-generation^[2] sulfonylurea. Gliclazide was proven to protect human pancreatic beta-cells from hyperglycemia-induced apoptosis.^[3] It was also shown to have an antiatherogenic effect (preventing accumultaion of fat in arteries) in type 2 diabetes.^[4]

Form and composition

Each immediate-release tablet contains 80 mg. Modified release formulations contain 30 mg and 60 mg of gliclazide.

Indication

Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes mellitus of stable, mild, non-ketosis prone, type 2 diabetes. It is used when diabetes cannot be controlled by proper dietary management and exercise or when insulin therapy is not appropriate.^{[citation needed]} National Kidney Foundation (2012 Update) claims that Gliclazide doesn't requires dosage uptitration even in end stage Kidney disease.

Mode of action

Gliclazide selectively binds to sulfonylurea receptors (SUR-1) on the surface of the pancreatic beta-cells. It was shown to provide cardiovascular protection as it does not bind to sulfonylurea receptors (SUR-2A) in the heart.^[5] This binding effectively closes the K+ ion channels. This decreases the efflux of potassium from the cell which leads to the depolarization of the cell. This causes voltage dependent Ca++ ion channels to open increasing the Ca++ influx. The calcium can then bind to and activate calmodulin which in turn leads to exocystosis of insulin vesicles leading to insulin release.^{[citation needed]}

Dosage

The dosage for the 80 mg formulation is 40 to 320 mg daily in two divided doses, while the 30 mg and 60 mg modified release formulation may be given at a dose of 30 to 120 mg once daily at breakfast.^{[citation needed]}

Properties

• Hypoglycemic sulfonylurea, restoring first peak of insulin secretion, increasing insulin sensitivity.^{[citation needed]}
• Glycemia-independent hemovascular effects, antioxidant effect.^{[citation needed]}
• No active circulating metabolites.^{[citation needed]}

Contraindications

• Type 1 diabetes^{[citation needed]}
• Hypersensitivity to sulfonylureas^{[citation needed]}
• Severe renal or hepatic failure^{[citation needed]}
• Pregnancy and lactation^{[citation needed]}
• Miconazole coprescription^{[citation needed]}

Metabolism

Gliclazide undergoes extensive metabolism to several inactive metabolites in humans, mainly methylhydroxygliclazide and carboxygliclazide. CYP2C9 is involved in the formation of hydroxygliclazde in human liver microsomes and in a panel of recombinant human P450sin vitro.^[6][7] But the pharmacokinetics of gliclazide MR are affected mainly by CYP2C19 genetic polymorphism instead of CYP2C9 genetic polymorphism.^[8][9]

Interactions

Hyperglycemic action may be caused by danazol, chlorpromazine, glucocorticoids, progestogens, or β-2 agonists. Its hypoglycemic action may be potentiated by phenylbutazone, alcohol, fluconazole, β-blockers, and possibly ACE inhibitors. It has been found that rifampin increases gliclazide metabolism in humans in vivo.^[10]

Adverse effects

• Hypoglycemia - while it was proven to have the same efficacy as glimepiride, one of the newer sulfonylureas, the European GUIDE study has shown that it has approximately 50% fewer confirmed hypoglycaemic episodes in comparison with glimepiride.^[11]
• Gastrointestinal disturbance (reported)^{[citation needed]}
• Skin reactions (rare)^{[citation needed]}
• Hematological disorders (rare)^{[citation needed]}
• Hepatic enzyme rises (exceptional)^{[citation needed]}

Overdosage

Gliclazide overdose may cause severe hypoglycemia, requiring urgent administration of glucose by IV and monitoring.^{[citation needed]}

References

External links

• Official website for Diamicron MR
• SERVIER
• Advance clinical trial on diabetes